Navamedic ASA: Second quarter results 2017
Oslo, 28 July 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 89.7 million in the second quarter of 2017 (NOK 66.7 million in Q2 2016), representing a growth of 34.4%, following the successful ramp-up of the TopRidge Pharma partnership. During the quarter, the company entered into an agreement with Orexigen Therapeutics, Ltd. for the distribution of prescription anti-obesity pharmaceutical, Mysimba(TM). Commercialisation of Sippi® continues to progress as planned, with the initiation of new clinical evaluations in new markets. "Navamedic had a strong second quarter in 2017,